Karyopharm Therapeut
(KPTI)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -93,841 | -60,714 | -23,462 | -76,422 | -45,642 |
| Depreciation Amortization | 7,977 | 5,093 | 2,415 | 4,205 | 2,159 |
| Accounts receivable | -1,111 | -2,166 | -4,477 | -3,804 | -4,816 |
| Accounts payable and accrued liabilities | 285 | -2,510 | 765 | 1,984 | 2,660 |
| Other Working Capital | 22,772 | 8,525 | -1,525 | -302 | -9,710 |
| Other Operating Activity | 377 | -5,909 | -12,700 | -53,147 | -46,327 |
| Operating Cash Flow | $-63,541 | $-57,681 | $-38,984 | $-127,486 | $-101,676 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -142 | -195 |
| Purchase Of Investment | N/A | N/A | N/A | -58,822 | -57,316 |
| Sale Of Investment | 38,378 | 33,573 | 15,288 | 154,437 | 138,187 |
| Investing Cash Flow | $38,378 | $33,573 | $15,288 | $95,473 | $80,676 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 83,300 | 83,300 |
| Common Stock Issued | 356 | 356 | N/A | 1,452 | 772 |
| Other Financing Activity | 0 | 0 | 0 | -43,106 | -43,106 |
| Financing Cash Flow | $356 | $356 | $N/A | $41,646 | $40,966 |
| Exchange Rate Effect | 15 | 13 | 5 | -11 | 9 |
| Beginning Cash Position | 62,814 | 62,814 | 62,814 | 53,192 | 53,192 |
| End Cash Position | 38,022 | 39,075 | 39,123 | 62,814 | 73,167 |
| Net Cash Flow | $-24,792 | $-23,739 | $-23,691 | $9,622 | $19,975 |
| Free Cash Flow | |||||
| Operating Cash Flow | -63,541 | -57,681 | -38,984 | -127,486 | -101,676 |
| Capital Expenditure | N/A | N/A | N/A | -142 | -195 |
| Free Cash Flow | -63,541 | -57,681 | -38,984 | -127,628 | -101,871 |